Nociceptive, neuropathic, or nociplastic low back pain? The low back pain phenotyping (BACPAP) consortium's international and multidisciplinary consensus recommendations.
СтатьяОбзорConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nijs Jo, Kosek Eva, Chiarotto Alessandro, Cook Chad, Danneels Lieven A, Fernández-de-Las-Peñas César, Hodges Paul W, Koes Bart, Louw Adriaan, Ostelo Raymond, Scholten-Peeters Gwendolyne G M, Sterling Michele, Alkassabi Othman, Alsobayel Hana, Beales Darren, Bilika Paraskevi, Clark Jacqui R, De Baets Liesbet, Demoulin Christophe, de Zoete Rutger M J, Elma Ömer, Gutke Annelie, Hanafi Rikard, Hotz Boendermaker Sabina, Huysmans Eva, Kapreli Eleni, Lundberg Mari, Malfliet Anneleen, Meziat Filho Ney, Reis Felipe J J, Voogt Lennard, Zimney Kory, Smeets Rob, Morlion Bart, de Vlam Kurt, George Steven Z
Аннотация
The potential to classify low back pain as being characterised by dominant nociceptive, neuropathic, or nociplastic mechanisms is a clinically relevant issue. Preliminary evidence suggests that these low back pain phenotypes might respond differently to treatments; however, more research must be done before making specific recommendations. Accordingly, the low back pain phenotyping (BACPAP) consortium was established as a group of 36 clinicians and researchers from 13 countries (five continents) and 29 institutions, to apply a modified Nominal Group Technique methodology to develop international and multidisciplinary consensus recommendations to provide guidance for identifying the dominant pain phenotype in patients with low back pain, and potentially adapt pain management strategies. The BACPAP consortium's recommendations are also intended to provide direction for future clinical research by building on the established clinical criteria for neuropathic and nociplastic pain. The BACPAP consortium's consensus recommendations are a necessary early step in the process to determine if personalised pain medicine based on pain phenotypes is feasible for low back pain management. Therefore, these recommendations are not ready to be implemented in clinical practice until additional evidence is generated that is specific to these low back pain phenotypes.